Rare lephants
Screener

Corcept Therapeutics Incorporated

CORT ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — Corcept Therapeutics Incorporated

Total Moat Score 14 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 4 / 5 Method-of-use and formulation patents around Korlym, plus two decades of proprietary clinical data on cortisol modulation, give Corcept a scientific head start that is hard to replicate quickly.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 2 / 5 Corcept has no manufacturing cost advantage; its edge is a lean, focused commercial model rather than production economics.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 3 / 5 Historically strong specialty-drug pricing on Korlym, but pricing power is now being eroded by Teva's generic and Corcept's own authorized generic.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 No network effects; value comes from clinical efficacy and physician relationships, not from user or platform scale.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 2 / 5 Once patients are stabilized on a cortisol modulator, physicians are somewhat reluctant to switch regimens, but generic entry lowers the practical switching barrier on price alone.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 3 / 5 Cushing's syndrome is a small, underdiagnosed market that does not attract many large competitors, giving Corcept effective scale advantages in a niche disease area.